Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapse-remitting Multiple Sclerosis”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Active Not RecruitingNCT07667322
What this trial is testing

Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Hoffmann-La Roche 75
Not applicableStudy completedNCT00787657
What this trial is testing

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Who this might be right for
Relapsing Remitting Multiple Sclerosis (RRMS)
Bayer 1,723
Large-scale testing (Phase 3)Study completedNCT01440101
What this trial is testing

Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

Who this might be right for
Multiple Sclerosis
Biogen 106
Early research (Phase 1)Study completedNCT00559702
What this trial is testing

Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)

Who this might be right for
Relapsing-Remitting Multiple SclerosisSecondary Progressive Multiple Sclerosis
Biogen 76
Not applicableStudy completedNCT01564511
What this trial is testing

Effects of Electromechanical Gait Trainer in Patients With Multiple Sclerosis

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Universita di Verona 50
Not applicableUnknownNCT05648292
What this trial is testing

The Relationships Between Personal Identity, Autobiographical Memory and Future Thinking in People With Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-RemittingHealthy Controls
Centre d'Investigation Clinique et Technologique 805 90
Post-approval studies (Phase 4)Study completedNCT01585298
What this trial is testing

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Who this might be right for
Multiple Sclerosis
Novartis Pharmaceuticals 6,998
Not applicableUnknownNCT01250678
What this trial is testing

Neurocognitive Changes in Patients With Remitting Relapsing Multiple Sclerosis Treated With Natalizumab

Who this might be right for
Multiple SclerosisCognitive Impairment
Cantonal Hospital of St. Gallen 50
Not applicableStudy completedNCT01142518
What this trial is testing

An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Merck KGaA, Darmstadt, Germany 86
Post-approval studies (Phase 4)Study completedNCT04261790
What this trial is testing

Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Johns Hopkins University 10
Not applicableUnknownNCT05510817
What this trial is testing

Multiparametric Assessment to Investigate Prognostic Factors for Disease Evolution a nd Evolutionary Patterns of Cognitive Status in RRMS

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
University Hospital of Mont-Godinne 50
Testing effectiveness (Phase 2)Looking for participantsNCT07776743
What this trial is testing

Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Relapsing-remitting Multiple Sclerosis (RRMS)
Guangzhou Lupeng Pharmaceutical Company LTD. 30
Large-scale testing (Phase 3)Ended earlyNCT03085810
What this trial is testing

Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Hoffmann-La Roche 1,225
Testing effectiveness (Phase 2)Ended earlyNCT04971005
What this trial is testing

Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Universitätsklinikum Hamburg-Eppendorf 1
Large-scale testing (Phase 3)Study completedNCT00030966
What this trial is testing

Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Biogen 1,200
Not applicableUnknownNCT04121637
What this trial is testing

To Investigate the Effect of Aerobic Exercise on Neurophysiological Values and Functionality in Individuals With Multiple Sclerosis.

Who this might be right for
Multiple Sclerosis, Relapsing-RemittingFNDC5Irisin Hormone+2 more
Firat University 22
Not applicableStudy completedNCT01112345
What this trial is testing

An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Merck KGaA, Darmstadt, Germany 133
Large-scale testing (Phase 3)Study completedNCT00289978
What this trial is testing

Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Who this might be right for
Relapsing-remitting Multiple Sclerosis
Novartis 1,272
Post-approval studies (Phase 4)Ended earlyNCT01436643
What this trial is testing

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Who this might be right for
DepressionRelapsing-remitting Multiple Sclerosis
Novartis Pharmaceuticals 54
Post-approval studies (Phase 4)Active Not RecruitingNCT05296161
What this trial is testing

B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Amsterdam UMC, location VUmc 296
Next Page